Purchase by John Brendan Doyle (Chief Financial Officer)
10,000 shares · @ $1.13 · $11,300
Cognition Therapeutics, Inc. Common Stock · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · Now $1.25
-7.8% in 3d after detection
Post-detection moves
1h
—
1d
0.0%
3d
-7.8%
7d
-3.1%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS